Proteins play an important part in early discovery as both targets for therapeutics as well as potential therapeutics themselves. As targets as
well as therapeutics, it is important to produce proteins for screening and developing both small molecules as well as biological therapeutics. The global revenue of the total proteomics market is anticipated to grow
at a compound annual growth rate of about 4.1% to about $9.2 billion by 20181.
On September 4, 2014, we announced that we expanded into the protein market, with an initial focus on protein expression and purification. Our current and ongoing activities – as part of our New York State Public-Private Partnership in Buffalo, N.Y. – encompass the production of purified recombinant proteins as reagents and tools for biological assays and sterile, pyrogen-free materials for proof-of-concept, non-human in vivo studies.
Please contact us to find out more about our services, expertise and capabilities in this area, or to request a quote.
Current production capabilities range from a scale of 1 to 100 milligrams. We are very excited to be able to offer these expanded biology services as we continue to work with our customers, partners, CNSE, and the State of New York, to provide relevant drug discovery services, cutting-edge platforms and expertise to academia and the global Bio-Pharmaceutical industry.
Some of the benefits of working with us in this area include the flexibility of starting points and access to cutting-edge technologies that provide faster methods for materials for our customers in this area. The protein expression systems and methods of focus are E. coli, mammalian and baculovirus. Our protein expression group produces large-scale batches of multimeric protein complexes, such as Wnt/Frizzle, pictured above.
For example, flow-through electroporation – a technology that is superior to older and more widely utilized lipid-based transfection methods – is used to generate both high-yield transient and stably expressing cell lines. In addition, for protein production from mammalian cells, we offer flow through electroporation followed by transient expression as a faster method for the production of proof-of-concept and single use materials (biologics and reagents, respectively).
Biology, discovery biology, E. Coli, electroporation, flow-through electroporation, protein, Protein Expression, purification